Yves FradetM.D.

Lambert M, Benmoussa A, Diallo I, Ouellet-Boutin K, Dorval V, Majeau N, Joly-Beauparlant C, Droit A, Bergeron A, Têtu B, Fradet Y, Pouliot F, Provost P

Identification of Abundant and Functional dodecaRNAs (doRNAs) Derived from Ribosomal RNA.

Int J Mol Sci, 22 (18), 2021.

Abstract | Links:

Kourbanhoussen K, Joncas FH, D Wallis CJ, Hovington H, Dagenais F, Fradet Y, Guillemette C, Lacombe L, Toren P

Follicle-stimulating hormone (FSH) levels prior to prostatectomy are not related to long-term oncologic or cardiovascular outcomes for men with prostate cancer.

Asian J Androl, 2021.

Abstract | Links:

Otis-Chapados S, Goulet CR, Dubois G, Lavallee E, Dujardin T, Fradet Y, Lacombe L, Lodde M, Tiguert R, Toren P, Fradet V, Beauregard JM, Buteau FA, Pouliot F

F-Fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is accurate for high-grade prostate cancer bone staging when compared to bone scintigraphy.

Can Urol Assoc J, 2021.

Abstract | Links:

Powles T, Csoszi T, Ozguroglu M, Matsubara N, Geczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Morales Barrera R, Flechon A, Gunduz S, Loriot Y, Rodriguez-Vida A, Mamtani R, Yu EY, Nam K, Imai K, Homet Moreno B, Alva A, Cascallar DV, Varela M, Lazzaro MF, Kaen DL, Gatica G, Flores DH, Falco A, Molina M, Van Aelst F, Sautois B, Machiels JP, Schallier D, Brust L, Rapatoni L, Azevedo SJ, Marinho G, Soares JPH, Dzik C, Almeida Silva J, Fay AP, Gingerich J, Ferrario C, Potvin K, Vanhuyse M, Abdelsalam M, Caglevic C, Reyes F, Leal JL, Francisco F, Ibanez C, Joly F, Laguerre B, Ladoire S, Topart D, Huillard O, Gross-Goupil M, Culine S, Gravis G, Reichardt P, Retz M, Herden J, Pfister D, Ohlman C, Stoeckle M, Wirth M, Lorch A, Niegisch G, Goebell PJ, Boegemann M, Merseburger A, Gakis G, Bedke J, Neisius A, Thomas C, Hoefner T, Telekes A, Kosa JE, Revesz J, Bodoky G, Csejtei A, Ruzsa A, Kolonics Z, Erfan J, McDermott R, Bambury R, Sella A, Frank SJ, Kejzman D, Goldman O, Rosenbaum E, Peer A, Berger R, Rouvinov K, Sarid D, Fukasawa S, Arai G, Yamaguchi A, Yokomizo A, Takayama T, Kinoshita H, Kikuchi E, Mizuno R, Fujii Y, Sassa N, Matsukawa Y, Fujimoto K, Tanikawa T, Tomita Y, Nishimura K, Tsujihata M, Oyama M, Masumori N, Kanayama H, Takano T, Miura Y, Miyazaki J, Joraku A, Kimura T, Yamamoto Y, Kobayashi K, De Wit R, Aarts M, Gerritsen W, Los M, Beerepoot L, Izmailov A, Gorelov SI, Alekseev BY, Semenov A, Kostorov VA, Zyryanov A, Oschepkov VN, Shidin VA, Vladimirov VI, Gafanov RA, Karlov PA, Anderson DB, Shepherd L, Cohen GL, Rapoport BL, Ruff P, Lee N, Bae WK, Herranz UA, Grande E, Alonso Gordoa T, Guma Padro J, Gauna DC, Arranz JA, Munoz Langa J, Sarrio RG, Montesa Pino A, Juan Fita MJ, Su YL, Lin YC, Shen YC, Chang YH, Huang YH, Sriuranpong V, Chansriwong P, Srimuninnimit V, Danchaivijitr P, Abali H, Yavuz S, Ozyilkan O, Sendur MAN, Ekenel M, Arslan C, Ozdogan M, Birtle A, Huddart R, de Santis M, Zarkar A, Evans L, Hussain S, DiSimone C, Muina AF, Schlegel P, Jhangiani HS, Harrison M, Slater DE, Wright D, Percent IJ, Hwang C, Gupta S, Bajaj M, Galamaga R, Eklund J, Wallace J, Shtivelband M, Suh JJ, Burhani N, Eadens M, Gunturu K, Burgess E, Wong J, Chaudhry A, Van Veldhuizen P, Graff S, Schnadig ID, Carneiro B, Morgans A, Fitzharris JT, Oliff IA, Vuky J

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.

Lancet Oncol, 22 (7), 2021.

Abstract | Links:

Gevariya N, Lachance G, Robitaille K, Joly Beauparlant C, Beaudoin L, Fournier E, Fradet Y, Droit A, Julien P, Marette A, Bergeron A, Fradet V

Omega-3 Eicosapentaenoic Acid Reduces Prostate Tumor Vascularity.

Mol Cancer Res, 19 (3), 2021.

Abstract | Links:

Bilodeau JF, Gevariya N, Larose J, Robitaille K, Roy J, Oger C, Galano JM, Bergeron A, Durand T, Fradet Y, Julien P, Fradet V

Long chain omega-3 fatty acids and their oxidized metabolites are associated with reduced prostate tumor growth.

Prostaglandins Leukot Essent Fatty Acids, 164 , 2021.

Abstract | Links:

Toren P, Brisson H, Simonyan D, Hovington H, Lacombe L, Bergeron A, Fradet Y

Androgen receptor and immune cell PD-L1 expression in bladder tumors predicts disease recurrence and survival.

World J Urol, 39 (5), 2021.

Abstract | Links:

Vittrant B, Bergeron A, Molina OE, Leclercq M, Legare XP, Hovington H, Picard V, Martin-Magniette ML, Livingstone J, Boutros PC, Collins C, Fradet Y, Droit A

Immune-focused multi-omics analysis of prostate cancer: leukocyte Ig-Like receptors are associated with disease progression.

Oncoimmunology, 9 (1), 2020.

Abstract | Links:

Vittrant B, Leclercq M, Martin-Magniette ML, Collins C, Bergeron A, Fradet Y, Droit A

Identification of a Transcriptomic Prognostic Signature by Machine Learning Using a Combination of Small Cohorts of Prostate Cancer.

Front Genet, 11 , 2020.

Abstract | Links:

Turcotte B, Paquet S, Blais AS, Blouin AC, Bolduc S, Bureau M, Caumartin Y, Cloutier J, Deschenes-Rompre MP, Dujardin T, Fradet Y, Lacombe L, Moore K, Morin F, Nadeau G, Simonyan D, Soucy F, Tiguert R, Toren P, Lodde M, Pouliot F

A prospective, multisite study analyzing the percentage of urological cases that can be completely managed by telemedicine.

Can Urol Assoc J, 14 (10), 2020.

Abstract | Links: